Anumeha Whisenhunt, DO
Vascular Surgery · Atlanta, GANPI 1538499058
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (39.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Aroa Biosurgery Incorporated at 27.3% of the total. 2025 is the largest year on record at $20,217, more than ten times the $442 reported in 2019. Among vascular surgery clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 141 payments — averaging $233.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aroa Biosurgery Incorporated$9K
- Cardiva Medical, Inc.$8K
- Medtronic$6K
- Penumbra, Inc.$4K
- W. L. Gore & Associates, Inc.$3K
- Silk Road Medical, Inc.$929
- plus $2K from 31 others
What the payments were for
- Consulting fees$4,20013%
- Speaking & faculty fees$8,80027%
- Travel & lodging$12,92039%
- Food & beverage$7,00621%
- Education$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aroa Biosurgery Incorporated | 6 | $8,999 |
| Cardiva Medical, Inc. | 8 | $7,660 |
| Medtronic(2 entities) | 9 | $5,769 |
| Penumbra, Inc. | 19 | $3,923 |
| W. L. Gore & Associates, Inc. | 30 | $3,203 |
| Silk Road Medical, Inc. | 9 | $929 |
| Terumo Medical Corporation | 5 | $315 |
| Endologix LLC | 4 | $313 |
| Boston Scientific | 3 | $179 |
| Cook Medical LLC | 2 | $172 |
| Shape Memory Medical Inc. | 1 | $150 |
| Argon Medical Devices, Inc. | 3 | $115 |
| Kerecis Limited | 1 | $100 |
| Angiodynamics, Inc. | 3 | $95 |
| Inari Medical, Inc. | 3 | $92 |
| Humacyte Global, Inc. | 2 | $89 |
| Polynovo North America LLC | 3 | $87 |
| Shockwave Medical, Inc | 3 | $74 |
| Abbott | 1 | $70 |
| Surmodics, Inc. | 1 | $64 |
| Pfizer | 3 | $63 |
| Bard Peripheral Vascular, Inc. | 2 | $56 |
| Lemaitre Vascular, Inc. | 3 | $54 |
| Johnson & Johnson(2 entities) | 2 | $53 |
| Siemens Medical Solutions USA, Inc. | 2 | $49 |
| Solventum Corporation | 2 | $46 |
| BD | 1 | $32 |
| Imperative Care, Inc | 1 | $32 |
| Convatec Inc. | 1 | $28 |
| Cordis US CORP. | 1 | $25 |
| Stimlabs LLC | 1 | $22 |
| Philips North America LLC | 1 | $22 |
| Stryker | 1 | $20 |
| Acera Surgical, Inc. | 1 | $20 |
| EKOS Corporation | 1 | $19 |
| Access Pro Medical, LLC | 1 | $18 |
| Mimedx Group, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cardiva VASCADE MVP VVCS 6-12F$7,508
- Indigo System$3,698
- ENROUTE Transcarotid Neuroprotection System$1,010
- GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis$798
- GORE TAG Conformable Thoracic Stent Graft$605
- ENROUTE Transcarotid Stent System$493
- ENHANCE Transcarotid Peripheral Access Kit$493
- ENROUTE 0.014 Guidewire$493
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$404
- Kerecis SurgiClose$402
- GORE TAG Thoracic Endoprosthesis$301
- HawkOne$260
- GORE TAG Thoracic Branch Endoprosthesis$197
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$186
- ENROUTE Transcarotid Stent$186
- GlideWire$178
- Cook$164
- IMPEDE EMBOLIZATION PLUG$150
- Abre$140
- GORE VIABAHN VBX Balloon Expandable Endo$127
How this compares
$32,977 in reported general payments places this provider in the 90th percentile of 176 vascular surgery providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 15 | $17,501 |
| Cilostazol | 42 | $1,116 |
| ClopidogrelClopidogrel Bisulfate | 24 | $364 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $53 | $17,50115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 176 vascular surgery providers in Georgia.
Other vascular surgery in Atlanta
- Siddharth PatelAtlanta$303K
- Walaya Methodius-RayfordAtlanta$79K
- Andrew UnzeitigAtlanta$46K
- Yazan DuwayriAtlanta$44K
- James ChangAtlanta$31K
- Chad AlemanAtlanta$21K
- Olamide AlabiAtlanta$19K
- Jorge CorsoAtlanta$18K
- Peter H DoublerAtlanta$15K
- Eyal Ben-ArieAtlanta$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.